Therefore, angiogenic therapy with VEGF is a clinically promising strategy for ischemic diseases.16,17 For example, MSCs have the potency to promote angiogenesis via paracrine effects from angiogenic factors such as VEGF.18 Various studies also have reported that MSCs are involved in angiogenesis and are useful in improving different ischemic diseases, such as hindlimb ischemia.19 However, due to the heterogeneity of MSCs, the detailed molecular mechanisms that optimize their angiogenic effect are not well understood. The gene discussed is VEGFA; the disease is ischemic disease.